Walthall Howard 4
4 · Organogenesis Holdings Inc. · Filed Dec 12, 2018
Insider Transaction Report
Form 4
Walthall Howard
Exec. VP, Strat. & Mkt Dev.
Transactions
- Award
Stock Option (Right to Buy)
2018-12-10+85,710→ 85,710 totalExercise: $3.46Exp: 2027-05-04→ Common Stock (85,710 underlying) - Award
Stock Option (Right to Buy)
2018-12-10+203,000→ 203,000 totalExercise: $3.46Exp: 2027-05-04→ Common Stock (203,000 underlying)
Footnotes (4)
- [F1]100% of the shares subject to this option are fully vested and exercisable.
- [F2]Received in connection with the Issuer's business combination (the "Merger") with Organogenesis Inc. ("Organogenesis") in accordance with the terms of the Agreement and Plan of Merger dated as of August 17, 2018 among the Issuer, which was then referred to as Avista Healthcare Public Acquisition Corp., Avista Healthcare Merger Sub, Inc. and Organogenesis, in exchange for an option to acquire 42,222 shares of common stock of Organogenesis for $7.01 per share.
- [F3]The shares underlying the option shall vest 20% annually beginning on December 31, 2018.
- [F4]Received in connection with the Merger in exchange for an option to acquire 100,000 shares of common stock of Organogenesis for $7.01 per share.